Last reviewed · How we verify
PCSK9 inhibitor plus statin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
PCSK9 inhibitor plus statin (PCSK9 inhibitor plus statin) — Beijing Anzhen Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PCSK9 inhibitor plus statin TARGET | PCSK9 inhibitor plus statin | Beijing Anzhen Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PCSK9 inhibitor plus statin CI watch — RSS
- PCSK9 inhibitor plus statin CI watch — Atom
- PCSK9 inhibitor plus statin CI watch — JSON
- PCSK9 inhibitor plus statin alone — RSS
Cite this brief
Drug Landscape (2026). PCSK9 inhibitor plus statin — Competitive Intelligence Brief. https://druglandscape.com/ci/pcsk9-inhibitor-plus-statin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab